Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells

Cells degrade proteins either by proteasomes that clinically are targeted by for example bortezomib or carfilzomib, or by formation of autophagosomes and lysosomal degradation that can be inhibited by hydroxychloroquine (HCQ). Multiple myeloma is unique among cancers because proteasomal inhibition h...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Baranowska, Katarzyna, Misund, Kristine, Starheim, Kristian K., Holien, Toril, Johansson, Ida, Darvekar, Sagar, Buene, Glenn, Waage, Anders, Bjørkøy, Geir, Sundan, Anders
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342593/
https://ncbi.nlm.nih.gov/pubmed/27683126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12226
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky